Gilead Sciences Inc. (GILD)
Gilead Sciences (GILD) Rises Higher Than Market: Key Facts
Gilead Sciences (GILD) closed the most recent trading day at $157.48, moving +2.57% from the previous trading session.
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Gilead Sciences (GILD) Laps the Stock Market: Here's Why
Gilead Sciences (GILD) closed the most recent trading day at $151.17, moving +2.77% from the previous trading session.
Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know
Gilead Sciences (GILD) closed the most recent trading day at $144.74, moving 1.87% from the previous trading session.
More Upside Awaits for Gilead Sciences Stock. Stay Invested.
Gilead shares are up 35% since Barron's highlighted them, but our catalysts have yet to fully play out.
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It
Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know
Recently, Zacks.com users have been paying close attention to Gilead (GILD). This makes it worthwhile to examine what the stock has in store.
Gilead Expands Lenacapavir Access With New PAHO Deal in Latin America
GILD's PAHO deal expands twice-yearly lenacapavir access across Latin America and the Caribbean, adding 14 countries to its global access strategy.
Gilead Sciences Sees Yeztugo Powering HIV Growth as Oncology Pipeline Advances
Gilead Sciences NASDAQ: GILD executives outlined plans to expand the company's HIV prevention and treatment franchises while advancing oncology and inflammation programs, with Chairman and Chief Executive Officer Dan O'Day describing the company as being at an “inflection point in value.”
Gilead Sciences (GILD) Gains As Market Dips: What You Should Know
In the closing of the recent trading day, Gilead Sciences (GILD) stood at $146.42, denoting a +1.88% move from the preceding trading day.
Gilead Sciences Sees Sunlenca Launch Fueling Long-Term HIV Growth
Gilead Sciences NASDAQ: GILD CFO Andy Dickinson told attendees at the Cantor Global Healthcare Conference that the company sees continued growth opportunities across its HIV prevention and treatment businesses, while advancing programs in inflammation, oncology and cell therapy.
Gilead Sciences, Inc. (GILD) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Gilead Sciences, Inc. (GILD) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
